Treatment of breast cancer

Compounds of the class of 4-oxo-butenoic acid derivatives are disclosed along with the surprising use property of these compounds as a anti-tumor agents in humans against breast carcinoma, which include: 2-(N\u27-Fluoren-9-ylidene-hydrazino)-5,5-dimethyl-4-oxo-hex-2-enoic acid methyl ester (OF-06), 1-(2,4-Dimethyl-phenyl)-2,4-dihydroxy-3-4-methyl-benzoyl)-5-oxo-2,5-dihydro-1H-pyrrole-2-carboxylic acid methyl ester (1F-07), 4-(4-Methoxy-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid (3F-10), 4-(4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid ethyl ester (3F-11), 2-Hydroxy-4-oxo-4-(2,3,5,6-tetrafluoro-4-methoxy-phenyl)-but-2-enoic acid (3F-15), and 4,4-Dihydroxy-5-4-methyl-benzoyl)-2-phenyl-2,4-dihydro-pyrazol-3-one (3F-16) as well as some novel derivatives of these compounds claimed (see Table 2). The invention also encompasses a class of the compounds with the novel property of anti-tumor activity against human breast cancer, which includes the following compounds 4-(4-Ethoxy-phenyl)-2-(N\u27-fluoren-9-ylidene-hydrazino)-2-hydroxy-4-oxo-butyric acid methyl ester (OF-13); 2-{N\u27-[1-(4-Chloro-phenyl)-ethylidene]-hydrazino}-4-oxo-4-phenyl-but-2-enoic acid methyl ester (OF-20); 2-(N\u27-Fluoren-9-ylidene-hydrazino)-4-oxo-4-phenyl-but-2-enoic acid methyl ester (1F-04); and 4-Chloro-4-(4-ethoxy-phenyl)-2-(fluoren-9-ylidene-hydrazono)-but-3-enoic acid methyl ester (3F-19)

Treatment of breast cancer

Compounds of the class of 4-oxo-butenoic acid derivatives are disclosure along with the surprising use property of these compounds as an anti-tumor agents in humans against breast carcinoma, which includes; 2-(N\u27-Fluoren-9-ylidene-hydrazino)-5,5-dimethyl-4-oxo-hex-enoic acid methyl ester (OF-06), 1-(2,4-Dimethyl-phenyl)-2,4-dihydroxy-3-(4-methyl-benzoyl)-5-oxo-2,5-dihydro-1H-pyrrole-2-carboxylic acid methyl ester (IF-07), 4-(4-Methoxy-phenyl)-2,4-dioxo-3-(phenyk-hydrazono)-butyric acid (3F-10, 4-(4-Chloro-phenyl)-2,4-dioco-3-(phenyl-hydrzono)-butyric acid ehtyl ester (3F-11), 2-Hyroxy-4-oxo-4-(2,3,5,6-tetrafluoro-4-methoxy-phenyl)-but-2-enoic acid (3F-15), and 4, 4-Dihyroxy-5-(4-methyl-benzoyl)-2-phenyl-2,4-dihdro-pyrazol-3-one (3F-16) as well as some novel derivatives of these compounds claimed. The invention also encompasses a class of the compounds with the novel property of anti-tumor activity agains human breast cancer, which includes the following compounds4-(4-Ethoxy-phenyl)-2-(N\u27-[1-(4-Chloro-phenyl)-ethylidene-hydrazino-2-hydroxy-4-oxo-butyric acid methyl ester (OF-13); 2-{N\u27-[1-(4-Chloro-phenyl)-ethylidene]-hydrazino]-4-oxo-4-phenyl-but-2-enoic-acid methyl ester (1F-04); amd 4-Chloro-4-(4-ethoxy-phenyl)-2-(fluoren-9-ylidene-hydrazono)-but-3-enoic acid methyl ester (3F-19)

Российские социологические и психологические исследования семьи в XXI веке: мета-анализ

В статье представлен анализ специфики публикаций в российских социологических и психологических научных журналах, посвященных исследованию семьи. Проанализированы тексты четырех научных изданий соответствующего профиля за 2000-2016 гг. Данные этого обзора частично сопоставимыми с результатами анализа статей за 1986-1991 гг., что позволяет оценить некоторые изменения. На основе качественно-количественного анализа ряда показателей сделаны выводы о специфике научных парадигм и состоянии «“нормальной” науки» (по Т. Куну) применительно к российской социологии и психологии семьи. Для последней семья, судя по публикациям в научных журналах, – малозначимый объект изучения, она рассматривается как фон для изучения личности (преимущественно ребенка) и межличностных отношений. Гетерогенность такого объекта исследования обуславливает выраженный интерес психологов к методической оснащенности и большему разнообразию методов сбора эмпирической информации, а также сопровождается фрагментацией профессионального сообщества по «школьно-журнальному» (речь здесь про научные школы) принципу. В российской социологии семьи значимость исследований семьи варьирует, но ее парадигма дуалистична (при доминировании естественно-научной); более согласована и стабильна, междисциплинарно открыта, ориентирована преимущественно на изучение структуры семьи и взаимодействие семьи с другими социальными институтами. При такой исследовательской оптике для исследователей фоном становится личность (супругов и детей). А «школьно-журнальная» фрагментированность российских социологов семьи проявляется по отношению не к отечественным, а к зарубежным авторам, что требует усиления междисциплинарного взаимодействия исследователей семьи

Treatment of breast cancer

Compounds of the class of 4-oxo-butenoic acid derivatives are disclosed along with the surprising use property of these compounds as a anti-tumor agents in humans against breast carcinoma, which include: 2-(N\u27-Fluoren-9-ylidene-hydrazino)-5,5-dimethyl-4-oxo-hex-2-enoic acid methyl ester (0F-06), 1-(2,4-Dimethyl-phenyl)-2,4-dihydroxy-3-(4-methyl-benzoyl)-5-oxo-2,5-dihydro-1H-pyrrole-2-carboxylic acid methyl ester (1F-07), 4-(4-Methoxy-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid (3F-10), 4-(4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid ethyl ester (3F-11), 2-Hydroxy-4-oxo-4-(2,3,5,6-tetrafluoro-4-methoxy-phenyl)-but-2-enoic acid (3F-15), and 4,4-Dihydroxy-5-(4-methyl-benzoyl)-2-phenyl-2,4-dihydro-pyrazol-3-one (3F-16) as well as some novel derivatives of these compounds claimed (see Table 2). The invention also encompasses a class of the compounds with the novel property of anti-tumor activity against human breast cancer, which includes the following compounds 4-(4-Ethoxy-phenyl)-2-(N\u27-fluoren-9-ylidene-hydrazino)-2-hydroxy-4-oxo-butyric acid methyl ester (0F-13); 2-{N\u27-[1-(4-Chloro-phenyl)-ethylidene]-hydrazino}-4-oxo-4-phenyl-but-2-enoic acid methyl ester (0F-20); 2-(N\u27-Fluoren-9-ylidene-hydrazino)-4-oxo-4-phenyl-but-2-enoic acid methyl ester (1F-04); and 4-Chloro-4-(4-ethoxy-phenyl)-2-(fluoren-9-ylidene-hydrazono)-but-3-enoic acid methyl ester (3F-19)

Treatment of breast cancer

Compounds of the class of 4-oxo-butenoic acid derivatives are disclosed along with the surprising use property of these compounds as a anti-tumor agents in humans against breast carcinoma, which include: 2-(N\u27-Fluoren-9-ylidene-hydrazino)5,5-dimethyl-4-oxo-hex-2-enoic acid methyl ester (OF-06), 1-(2,4-Dimethyl-phenyl)-2,4-dihydroxy-3-(4-methyl-benzoyl)-5-oxo-2,5-dihydro-1H-pyrrole-2-carboxylic acid methyl ester (1F-07), 4-(4-Methoxy-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid (3F-10), 4-(4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid ethyl ester (3F-11), 2-Hydroxy-4-oxo-4-(2,3,5,6-tetrafluoro-4-methoxy-phenyl)-but-2-enoic acid (3F-15), and 4,4-Dihydroxy-5-(4-methyl-benzoyl)-2-phenyl-2,4-dihydro-pyrazol-3-one (3F-16) as well as some novel derivatives of these compounds claimed (see Table 2). The invention also encompasses a class of the compounds with the novel property of anti-tumor activity against human breast cancer, which includes the following compounds 4-(4-Ethoxy-phenyl)-2-(N\u27-fluoren-9-ylidene-hydrazino)-2-hydroxy-4-oxo-butyric acid methyl ester (OF-13); 2-{N\u27-[1-(4-Chloro-phenyl)-ethylidene]-hydrazino}-4-oxo-4-phenyl-but-2-enoic acid methyl ester (OF-20); 2-(N\u27-Fluoren-9-ylidene-hydrazino)-4-oxo-4-phenyl-but-2-enoic acid methyl ester (1F-04); and 4-Chloro-4-(4-ethoxy-phenyl)-2-(fluoren-9-ylidene-hydrazono)-but-3-enoic acid methyl ester (3F-19

Treatment of colon cancer

The novel compound of the disclosure is 4-chloro-4-(4-ethoxy-phenyl)-2-(fluoren-9-ylidene-hydrazono)-but-3-enoic acid methyl ester (3F-19), and it alone or in combination with 4-(4-Ethoxy-phenyl)-2-(N\u27-fluoren-9-ylidene-hydrazino)-2-hydroxy-4-oxo-butyric acid methyl ester (OF-13), appears useful in humans as therapeutic means for the eradication of tumors from the human\u27s colon

Treatment of colon cancer

The novel compound of the disclosure is 4-chloro-4-(4-ethoxy-phenyl)-2-(fluoren-9-ylidene-hydrazono)-but-3-enoic acid methyl ester (3F-19), and it alone or in combination with 4-(4-Ethoxy-phenyl)-2-(N\u27-fluoren-9-ylidene-hydrazino)-2-hydroxy-4-oxo-butyric acid methyl ester (OF-13), appears useful in humans as therapeutic means for the eradication of tumors from the human\u27s colon

Methyl esters of substituted 4-OXO-2-butenoic acids for treatment of tuberculosis

A novel class of methyl esters of substituted 4-oxo-2-butenoic acids and their derivatives are disclosed along with the surprising use property of these compounds as a bacteriostatic agents for humans or non-humans against mycobacteria. These compounds include: 4-(4-Ethoxy-phenyl)-2-(N-fluoren-9-ylidene-hydrazino)-4-oxo-but-2-enoic acid methyl ester; 4-(4-Ethoxy-phenyl)-2-(N-fluoren-9-ylidene-hydrazino)-2-hydroxy-4-oxo-but yric acid methyl ester; 2-(4-Bromo-phenylamino)-5,5-dimethyl-4-oxo-hex-2-enoic acid methyl ester; A pharmaceutical composition is disclosed as well as the method of treating human and non-humans infected with M. tuberculosis and related mycobacteria

Study of acute and chronic toxicity of feed additive based on vermiculture

The paper presents the results of study of the toxicity of a feed additive, which includes Leuzea safflower (Rhaponticum carthamoides) and protein obtained from vermiculture. The acute toxicity of the feed additive was studied in 31 SD white rats. It has been established that the acute oral toxicity of the feed additive is above 2500 mg/kg, which makes it possible to classify the feed additive as hazard class 3 and classify it as “moderately hazardous” according to GOST 12.1.007-76. The chronic toxicity of the feed additive was studied in 22 SD white rats. The feed additive was administered orally at a dose of 120 and 1200 mg/kg for 30 days. Long-term effects were assessed 14 days after the last introduction of the feed additive. To assess the toxic effects, the effect of the additive on the general condition of the animals, food and water intake was evaluated, blood and urine were analyzed. Complete blood count was carried out by standard methods with the determination of the following parameters: hematocrit, hemoglobin level, the number of erythrocytes, platelets, leukocytes, eosinophils, segmented neutrophils, lymphocytes and monocytes. The study of biochemical parameters of blood was carried out using standard kits for biochemical analysis. The following indicators were determined: ALT, total bilirubin, glucose, creatinine and urea. The urinalysis included the determination of the following indicators: density, leukocytes, nitrites, pH, erythrocytes, protein,  glucose, ascorbic acid, ketones, urobilinogen, bilirubin. There was no statistically significant difference in blood and urine parameters between the animals of the control and experimental groups. A pathohistological examination of the stomach, liver, kidneys and heart was carried out, which showed the absence of a toxic effect of the feed additive. Local irritant action was studied in pathomorphological studies. It has been established that the feed additive does not have an irritating effect at the injection site. Thus, the feed additive can be used in feeding farm animals and birds at the recommended dose

Роль окислительного стресса в формировании кардиодепрессии при тяжелой изолированной черепно-мозговой травме (экспериментальное исследование)

Objective: to study the role of oxidative stress in the development of cardiac structural and metabolic disorders in severe isolated brain injury (BI). Materials and methods. The impact of BI on the parameters of serum chemilu-minescence and the contractility of isolated rat hearts were studied in experiments on 66 outbred male albino rats, as described by E. T. Fallen et al. Lipid peroxidation processes were inhibited, by intraperitoneally injecting the antioxidant carnosine (100 mg/kg) 1 and 24 hours before or just after BI. Results. The rate of free radical processes rose an hour after severe isolated BI, which was associated with the indirect signs of cardiomyocitic membrane damages, depressed rat heart contractility, and their diminished resistance to hypoxia, reoxygenation, and exercise by high rhythm. Administration of carnosine to the animals favored the normalization of chemluminescent values with the high overall antioxidative capacity of serum. The effect of the agent depended on the time of its use and it was high when carnosine was injected 1 and 24 hours before injury. At the stage of reoxygenation after the hypoxic test, there was a significant increase in evolving pressure, the rate of left ventricular myocardial contraction and relaxation, and a reduction in AsAT activity in all coronary duct tests, as compared with the controls. A negative correlation was found between the burst amplitude and the myocardial relaxation rate in the animals receiving the agent. Conclusion. Improved cardiac contractility and increased capacities of the mechanisms responsible for Ca2+ transport due to the use of the antioxidant carnosine allow one to state that oxidative stress is one of the pathogenetic factors of cardiac depression in severe isolated BI. Key words: brain injury, heart, oxidative stress, carnosine.Цель исследования — изучение роли окислительного стресса в формировании структурно-метаболических нарушений сердца при тяжелой изолированной черепно-мозговой травме (ЧМТ). Материал и методы. В экспериментах на 66 белых беспородных крысах-самцах изучено влияние ЧМТ на показатели хемилюминесценции сыворотки крови и сократимость изолированных сердец крыс по E. T. Fallen et al. Процессы липопероксида-ции ингибировали путем применения внутрибрюшинно за 24 и 1 ч до травмы или непосредственно после ЧМТ антиоксиданта карнозина (100 мг/кг). Результаты. Через 1 ч после тяжелой изолированной ЧМТ возрастала интенсивность свободнорадикальных процессов, что сочеталось с косвенными признаками повреждений мембран кардиомиоцитов, депрессией сократимости сердец крыс и снижением их устойчивости к гипоксии, реок-сигенации и нагрузке ритмом высокой частоты. Введение животным карнозина способствовало нормализации показателей хемилюминесцентного анализа на фоне высокой общей антиоксидантной способности сыворотки крови. Эффект препарата зависел от сроков его применения и был большим при использовании карнозина за 24 и 1 ч до травмы. На этапе реоксигенации после гипоксической пробы было отмечено достоверное увеличение, по отношению к группе сравнения, развиваемого давления, скорости сокращения и расслабления миокарда левого желудочка, а также снижение активности АсАТ во всех пробах коронарного протока. Была выявлена отрицательная корреляционная зависимость между амплитудой вспышки и скоростью расслабления миокарда получавших препарат животных. Заключение. Улучшение сократительной функции сердец травмированных крыс и увеличение мощности механизмов, ответственных за транспорт Са2+, при использовании антиоксиданта карнозина позволяет утверждать, что окислительный стресс является одним из патогенетических факторов кардиодепрессии при тяжелой изолированной ЧМТ. Ключевые слова: черепно-мозговая травма, сердце, окислительный стресс, карнозин